Download
1 / 1
10 likes | 72 Views
Amgen Canada partnered with H+K Canada for a robust public relations campaign to support the launch of PROLIA®, a targeted treatment for postmenopausal women at high risk for fracture. Through a blend of national media initiatives and unbranded public education forums, the campaign heightened awareness of osteoporosis, focusing on patient engagement and stakeholder collaboration. By leveraging partnerships with prominent organizations like Osteoporosis Canada and CARP, the program transcended expectations in both quantity and quality of coverage. The success was attributed to active involvement from physicians, stakeholders, and patients, along with a strategic blend of controlled and traditional media outreach tactics. The campaign not only closed the treatment gap but also shed light on PROLIA as a groundbreaking solution within the market.
E N D
A targeted approach to protecting bones Amgen Canada retained H+K Canada to develop and execute a public relations campaign to support the launch of PROLIA®, a unique, targeted treatment for postmenopausal women with osteoporosis at high risk for fracture. Our challenge was to generate attention for this often overlooked disease. We launched PROLIA with a national media campaign and eight unbranded public education forums held in partnership with stakeholder groups in communities across Canada. Ongoing stakeholder engagement and partnership – with Osteoporosis Canada and CARP – helped lay the groundwork for future advocacy and reimbursement efforts. Our program exceeded expectations in terms of quantity and quality of coverage; and its success, in large part, was due to the engagement and involvement of physicians, stakeholders and patients; a mix of controlled media and traditional media outreach tactics; as well as our ongoing consumer awareness campaign. Overall, we helped Amgen raise awareness of osteoporosis, the current treatment gap and PROLIA as a new treatment option.
